Skip to content

Study on the syndrome evolution law of liver stagnation spleen deficiency of IBS-D based on gene polymorphism of neurotransmitters related to brain gut axis

Study on the syndrome evolution law of liver stagnation spleen deficiency of IBS-D based on gene polymorphism of neurotransmitters related to brain gut axis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ROC-17012410
Enrollment
Unknown
Registered
2017-08-18
Start date
2017-08-21
Completion date
Unknown
Last updated
2017-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable Bowel Syndrome

Interventions

IBS-D stagnation of liver-QI with deficiency of the spleen group:venous blood sampling 15ml
IBS-D deficiency group of spleen and stomach group:venous blood sampling 15ml
IBS-D stagnation of liver Qi group:venous blood sampling 15ml
constipation predominant irritable bowel syndrome group:venous blood sampling 15ml
healthy control group :venous blood sampling 15ml

Sponsors

Second Affiliated Hospital of Guangzhou University of TCM
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Western medicine diagnostic criteria for IBS with diarrhea-predominant type belong to and comply with TCM liver spleen or weakness of the spleen stomach or stagnation of QI due to depression of the liver Permit, IBS with constipation-predominant type may be included in test cases in line; (2) Informed consent; (3) male or female patient between 18 to 65 years old.

Exclusion criteria

Exclusion criteria: 1. pregnancy, nursing mothers, or planning a pregnancy; 2. intestinal organic disease, such as inflammatory bowel disease, intestinal tuberculosis, colon polyps; 3. severe cardiovascular system, liver, kidney, hematopoietic system diseases and tumors of patients; 4. Gastrointestinal surgery record reports; 5. severe primary disease and mental illness; 6. There are drug and food allergies or allergies during the test; 7. Not signed informed consent; 8. It does not meet the inclusion criteria, according to the specified medication, can not determine the efficacy or incomplete information and other factors determine the efficacy or safety of persons; 9. researchers believe that clinical trials are not suitable for this study.

Design outcomes

Primary

MeasureTime frame
gene polymorphism of neurotransmitters related to brain gut axis;

Countries

China

Contacts

Public ContactHuang Shaogang

Second Affiliated Hospital of Guangzhou University of TCM

huangshaogang@126.com+86 13926451320

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026